
Canadian company, Aurinia Pharmaceuticals Inc. (AUPH) operates as a leading commercial-stage biopharmaceutical company. The company reported impressive financial results for the third quarter of fiscal 2024. Its revenue of $67.77 million surpassed the analysts’ expectations of $57.69 million. Also, AUPH’s EPS of $0.10 was above the estimate of $0.01.
Aurinia emphasizes the development and commercialization of therapies that target various diseases with insufficient medical reach. The company’s LUPKYNIS is used to treat adult patients with active lupus nephritis.